Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Francesca Nardi(Brigham and Women's Hospital), Karen Cichowski(Brigham and Women's Hospital)

Journal of Clinical Investigation

June 29, 2023

10.1172/jci167651

Cited by 20

Related Papers

The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor

|Cancer Cell|2013|135

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

|Cell Reports|2017|109

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

|Sarcoma|2019|74

DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130

|Scientific Reports|2019|58

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

|Nature|2024|56